Whitepapers

Pharmaceutical manufacturers depend on advanced blending systems for the injection, dispersion, and mixing of APIs, flavors, and lubricants before tableting, as well as for tablet blending and granulation. These systems use stainless steel contact surfaces and support continuous measuring, blending, and monitoring to maintain consistent product quality. This guide outlines which blender types are best suited for specific pharmaceutical applications.

This white paper explains how PK Blenders supports pharmaceutical manufacturers with precision blending and drying solutions designed to meet strict cGMP and regulatory requirements. It addresses key industry challenges such as blend uniformity, moisture control, particle protection, sanitation, and data integrity, while outlining equipment options tailored for solid dosage and API processing. As part of Carrier Process Equipment Group, PK Blenders can also integrate into complete, end-to-end pharmaceutical processing systems.

This white paper explores the critical role of thermal-processing technologies in pharmaceutical manufacturing, focusing on how drum dryers, vacuum dryers, and evaporators support consistent product quality, efficient solvent handling, and reliable moisture control. It outlines how these systems help manufacturers meet cGMP requirements, protect sensitive materials, and optimize upstream and downstream processes.

Streamline your workflow with smart automation

Explore key findings from LCGC user surveys on liquid chromatography—covering cost-performance, reliability, and evolving LC technology trends.

Discover our comprehensive portfolio of analytical HPLC solutions, featuring the latest Agilent Infinity III LC Series, applications, and a selection guide.

How lab managers and analytical scientists can maximize ROI, minimize hidden costs, and drive sustainable profitability with smarter LC decisions

Overcome common HPLC challenges. This eBook offers solutions to simplify routines, ensure reliable results, make smart investments, and create a sustainable lab

Capillary gel electrophoresis (CGE) is a high-resolution, label-free technique for the quality control of mRNA-based therapies. Because the poly(A) tail plays a critical role in mRNA stability and translation efficiency, accurately detecting and quantifying tailless species is essential to ensuring therapeutic efficacy and patient safety. This article explores how to optimize the SCIEX BioPhase™ 8800 system and RNA 9000 Purity & Integrity Kit to achieve the resolution required for today’s advanced mRNA medicines. Key method parameters, including electric field strength, capillary temperature, and sample concentration, are examined to support reliable separation and impurity detection.

In this case study, Colbert shares the methodology behind its robotic implementation, from defining the scope through vendor selection, design considerations and project wins.

An Overview of RFID Technology for Retail and Healthcare Packaging

Case study showcasing accelerated PPQ for an E. coli–expressed orphan therapy, achieving three PPQ batches in 18 months through high-compliance manufacturing.

Discover how a robust platform enables fast, high-quality bispecific antibody production by optimizing gene ratios, CLD, and analytics for purity and yield.

Discover the future of microbial expression with a platform that optimizes strain selection, expression systems, and purification methods, providing actionable insights in just eleven weeks.

This white paper explains the benefits and challenges of microbial-based fermentation for biologics, highlighting why processes often need to be custom-built for each molecule. Outlining a streamlined, cost-effective path that accelerates development from strain selection through tox material and early GMP, to reach IND and first-in-human trials faster.

Determining the optimal hybrid set-up can be challenging, with trade-offs in cost and flexibility. Our strategic framework helps you design the optimal mix for your facility.

The development of biologics, from initial molecule selection to commercial product, presents complex challenges related to stability, manufacturability, and immunogenicity. Skipping essential risk assessments can lead to costly consequences, including reformulation, reduced shelf life, additional testing, regulatory delays, or even project termination. Download this article to learn more about how a structured, data-driven developability workflow can de-risk biologics during early stages of development.